M. S. Gentile et al. in the study titled “Single-Fraction Radiotherapy for CD30+ Lymphoproliferative Disorders” in a retrospective review prominently assess the clinical response of refractory or recurrent CD30+ lymphoproliferative disorder lesions to palliative radiation therapy suggesting palliative localized RT for symptomatic CD30+ LPD refractory or recurrent to other therapies. The gene discussed is TNFRSF8; the disease is lymphoproliferative syndrome.